We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, an... Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, and acquisitions. The company's pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue and license revenue. Show more
Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2024 Annual Meeting of Stockholders on Wednesday, May 29, 2024, at 9:00 a.m. PT. The Annual Meeting will be...
– Company to present important new data from the Phase 2 SOLSTICE chronic hepatitis delta trial – – Conference call scheduled for June 5, 2024, at 6:00 a.m. ET / 12:00 p.m. CEST – Vir...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL Congress has changed the Company’s Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation...
– Late-breaker SOLSTICE data abstract accepted for poster presentation at the European Association for the Study of the Liver (EASL) Congress 2024 – – Two additional hepatitis program data...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities...
Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The...
– Over 60 participants dosed in two additional cohorts; initial data expected in the second quarter – – Approximately 50% of participants have compensated cirrhosis – Vir Biotechnology, Inc...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.11 | 11.5384615385 | 9.62 | 11.51 | 9.6 | 963450 | 10.84124168 | CS |
4 | 2.37 | 28.3492822967 | 8.36 | 11.51 | 8.2 | 939037 | 9.86914897 | CS |
12 | -0.45 | -4.02504472272 | 11.18 | 11.76 | 7.61 | 890196 | 9.70385433 | CS |
26 | 1.26 | 13.3051742344 | 9.47 | 12 | 7.61 | 1042263 | 9.88261801 | CS |
52 | -15.35 | -58.8573619632 | 26.08 | 27.48 | 7.61 | 1194738 | 11.76454428 | CS |
156 | -32.15 | -74.9766791045 | 42.88 | 58 | 7.61 | 1156228 | 24.38674592 | CS |
260 | -5.42 | -33.560371517 | 16.15 | 141.01 | 7.61 | 1124597 | 30.38280045 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions